Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Samaritan Pharmaceuticals, Inc.
Samaritan files provisional patent to support anti-cholesterol drug, cover new claims
June 23rd, 2006
Samaritan Pharmaceuticals Inc. (LIV) announced it has filed a new provisional U.S. patent application to support its original application and to add additional claims for its cardiovascular drug SP-1000 for the prevention and treatment of cardiovascular disease. Samaritan's collaborating scientists, through animal studies, validated SP-1000's ability to reduce blood cholesterol in animals. In addition, researchers validated SP-1000's ability, to clear clogged arteries of atheroma; raise HDL, the good cholesterol; and reduce CK enzyme elevations, a marker for heart suffering in animals. Researchers also have identified SP-1000 as having a new...
Source: Biotech Law Weekly (2006-06-23)
|
